Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
The FDA cleared an investigational new drug application for NTX-1024 ophthalmic solution in vernal keratoconjunctivitis, paving the way for a phase 2/3 clinical trial, according to a press release from NexEos Bio.
A randomized, double-masked, vehicle-controlled trial that will test the safety and efficacy of the eye drop is planned to begin later this year, according to the release.
According to NexEos, NTX-1024 neutralizes the eosinophil cationic protein-mediated inflammation that is involved in vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis.
“To our knowledge, NTX-1024